글로벌 선단비대증 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모                              

거대증은 사춘기와 성숙기 사이에 뇌하수체가 과도한 양의 성장 호르몬을 생성하여 발생하는 드문 호르몬 질환입니다. 뇌하수체 에서 생성되어 혈류로 방출되는 성장 호르몬 은 간에서 뼈와 조직의 성장을 자극하는 인슐린 유사 성장 인자-I(IGF-I)라는 호르몬을 생성하게 합니다. 성장 호르몬의 과다 생산으로 인해 과도한 수준의 IGF-I가 발생하면 연조직과 골격이 확장될 수 있습니다. 거대증은 중년층에서 가장 흔하지만 모든 연령대에서 영향을 미치거나 발병할 수 있습니다. 거대증은 인식하는 데 오랜 시간이 걸릴 수 있는 장애이며, 그 결과 주요 문제와 사망을 초래할 수 있습니다.

Data Bridge Market Research는 2021년에 선단비대증 시장이 15억 1,000만 달러 규모였으며 2029년까지 58억 1,000만 달러에 도달할 것으로 예상하고 2022년부터 2029년까지의 예측 기간 동안 8.00%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

시장 정의

말단비대증은 신체에 성장호르몬(GH)이 너무 많은 질환입니다. 비정상적인 GH는 일반적으로 이 질환을 유발하는 뇌하수체 종양을 제거하기 위한 수술로 교정합니다. 말단비대증은 종양이 너무 커서 완전히 제거할 수 없기 때문에 항상 치유되는 것은 아닙니다. 이 시나리오에서 말단비대증을 치료하기 위해 약물과 방사선( 방사선 요법 )을 사용할 수 있습니다. 약물은 수술적으로 제거하기 어려운 종양이 있는 일부 사람을 치료하는 데 사용됩니다. 이러한 약물은 뇌하수체가 GH를 생성하는 것을 막거나 신체의 다른 부분에서 작용하는 것을 막을 수 있습니다. 치료 후에는 매달 의사를 만나 뇌하수체가 제대로 기능하고 말단비대증이 재발하지 않았는지 확인해야 합니다. 평가는 최소한 1년에 한 번은 해야 합니다.

거대증 시장 동향

운전자

• 말단비대증 발병률 증가

말단비대증의 증가하는 발병률은 시장 성장률 확대로 이어질 주요 원동력으로 작용할 것입니다. 말단비대증과 뇌하수체 종양이 점점 더 흔해지고 있으며, 이는 시장 확장을 촉진하고 있습니다. 2021년 5월 "한국의 말단비대증에 대한 서술적 역학 및 생존 분석"이라는 제목의 연구에 따르면, 이 기간 동안 연평균 발병률은 100만 명당 4.2건이었고 유병률은 100만 명당 32.1건이었습니다. 말단비대증은 중년 성인에게 가장 흔히 진단되는 흥미로운 질병으로 10만 명당 5~8명에게 영향을 미칩니다.

• 의료 인프라에 대한 투자 증가

Another significant factor influencing the growth rate of acromegaly market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, surging number of government initiatives to spread awareness and rising prevalence of genetic diseases will result in the expansion of acromegaly market. Along with this, rising level of disposable income and changing lifestyle of people will enhance the growth rate of the market. The increasing incidence of hormonal diseases, such as hypopituitarism and endocrine diseases is estimated to enhance the market's growth rate.

Opportunities

• Rise in R & D activities  

The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the acromegaly market growth. Seven somatostatin analogues and two growth hormone receptor antagonists, for instance, are scheduled to be approved by the FDA by 2027. Furthermore, the introduction of technologically enhanced detection techniques such as radiosurgery and radio labelled imaging technologies that are cost effective and have little side effects is estimated to provide a growth platform for this industry.

Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the acromegaly market growth.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the growth rate of acromegaly market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the acromegaly market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This acromegaly market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acromegaly market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Acromegaly market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. 

COVID-19 Impact on Acromegaly Market

In the last year and a half, the majority of companies around the world have been adversely affected. This may be attributed to essential interruptions in their assembling and production network activities as a result of various preliminary lockdowns as well as various constraints imposed by overseeing specialists throughout the world. A similar situation exists in the global acromegaly market. Additionally, shopper demand has reduced along these lines, as people are now quicker to eliminate superfluous charges from their budgets, as this flare-up has severely hit most people's total financial situation.

These above-mentioned factors are expected to wreak havoc on the global acromegaly market's revenue trajectory over the forecast period. However, when individual administering professionals reduce these imposed restraints, the global acromegaly market is expected to recover as demand grows.

Recent Development

• In August 2020, Chiasma, Inc. announced the commercial launch and availability of MYCAPSSA (octreotide) capsules in the United States for patients with acromegaly. MYCAPSSA (octreotide) delayed-release capsules for oral administration are a somatostatin analog intended for long-term maintenance therapy in acromegaly patients who have responded to and tolerated octreotide or lanreotide treatment.

Global Acromegaly Market Scope

The acromegaly market is segmented on the basis of type, diagnosis, complications, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Complications

• Local
• Systemic
• CNS
• CVS
• Respiratory
• Endocrine and metabolic
• Neoplastic
• Skeletal
• Others
• Others

Type

• Ectopic Acromegaly
• Acromegaly Due to Growth Hormone

Diagnosis

• GH and IGF-I Measurement
• Growth Hormone Suppression Test
• Imaging
• Spine x-ray
• MRI of the brain, including the pituitary gland
• Echocardiogram
• Colonoscopy
• Others

Treatment

• Medication
• Somatostatin analogues
• Dopamine agonists
• Growth hormone antagonist
• Others
• Surgery
• Radiation
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Acromegaly Market Regional Analysis/Insights

The acromegaly market is analysed and market size insights and trends are provided by country, type, diagnosis, complications, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the acromegaly market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the acromegaly market because of the rising healthcare expenditure and increased high prevalence of pituitary tumor in this region. Additionally, the growing focus of major key players in research and development activities will further propel the market's growth rate.

Asia-Pacific is expected to grow significantly during the forecast period of 2022-2029 due to increased hormone related disorders and surgeries in this region. Also, development of healthcare infrastructure and large number of generic manufacturer will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Acromegaly Market Share Analysis

The acromegaly market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acromegaly market.

Some of the major players operating in the acromegaly market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 히크마 제약(영국)
• 브리스톨-마이어스 스퀴브 회사(미국)
• Bayer AG(독일)
• 베링거 인겔하임 인터내셔널 GmbH. (독일)
• Dr. Reddy's Laboratories Ltd. (인도)
• 길리드 사이언스 주식회사(미국)
• 암젠 주식회사(미국)
• 엘리 릴리 앤드 컴퍼니(미국)
• AbbVie Inc.(미국)
• 루팡(인도)
• 알러간(아일랜드)

SKU-53448